ClinicalTrials.gg
CompletedNCT04625946Updated Oct 6, 2026Results posted

Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation

A Phase 4 interventional study of Metformin and Recommendations for lifestyle modification. in Atrial Fibrillation, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of Michigan · Phase 4, Interventional, and Treatment

How we know

Updated Oct 6, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Atrial Fibrillation by University of Michigan — 2 open to participants now, 3 under way, none of them phase 3. Atrial Fibrillation · University of Michigan.

Started
2021
the only one that year
Phase 4
3 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Atrial Fibrillation by University of Michigan, this one is the only one that started in 2021, is one of 3 in phase 4, and was the 7th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 10 studies in Atrial Fibrillation by University of Michigan are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Atrial Fibrillation by University of Michigan, or all of them as a file.
02

Study summary

This clinical trial is being done to determine if metformin, a drug which is normally used in diabetes, can reduce atrial fibrillation in patients who are having an ablation for atrial fibrillation (AF). Atrial fibrillation is an abnormal heart rhythm which research has shown is related in part to obesity and diabetes.

It is anticipated that the participants treated in the metformin arm will have greater freedom from recurrent atrial arrhythmias after ablation.

Eligible participants enrolled in the trial will be assigned to one of the treatment arms (no treatment or metformin) and have follow-up visits up to approximately 1 year after the ablation. Additionally, all patients will also receive education on lifestyle changes and exercise which are standard of care.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • ablation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) >25 kilograms / square meter (kg/m2) with plan for rhythm control of atrial fibrillation by catheter ablation
  • All subjects must be able to understand and willing to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Individuals who are already taking metformin or other antidiabetic medications, including insulin
  • Known diabetes
  • Known allergy or Food and Drug Administration (FDA)-labeled to taking metformin (estimated (eGFR)\<30 millilitres per minute (mL/min)/1.73 square meters (m2), to metformin, acute or chronic metabolic acidosis)
  • Patients taking carbonic anhydrase inhibitors
  • eGFR below 30 mL/min per 1.73 m2 or other clinical diagnosis of advanced renal disease
  • Acute or chronic metabolic acidosis (serum bicarbonate \<22 milliequivalents per liter (mEq/L))
  • History of significant alcohol use (>2 drinks/day on average)
  • History of hepatic dysfunction (serum 1.5 times greater than )
  • History of (NYHA) Class III or IV heart failure
  • Pregnancy or nursing
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    Metformin

    Standard of care ablation with recommendations for lifestyle modification and metformin.

    Drug: Metformin · Behavioral: Recommendations for lifestyle modification. · Device: AliveCor

  • Other
    Standard of care

    Standard of care ablation with recommendations for lifestyle modification.

    Behavioral: Recommendations for lifestyle modification. · Device: AliveCor

Interventions

  • Metformin immediate release will be initiated at 250 milligrams (mg) daily (orally), and increased as tolerated to 2000 mg daily over a four week period. If a patient is unable to tolerate a dose increase they will return to their last tolerated dose after omitting one days dosing. 0 to Six weeks after the initiation of drug the patient will undergo (standard of care) ablation with the intent of achieving rhythm control. Participants will stay on the metformin 12 months after the ablation. In addition, all participants will receive education on lifestyle changes and exercise which are standard of care as well as have a discussion with their treating electrophysiologist and receive a handout.

    Also known as: Glucophage

  • BehavioralRecommendations for lifestyle modification.

    All subjects will receive education on lifestyle changes and exercise which are standard of care. This will include discussion with their treating electrophysiologist and a handout.

  • DeviceAliveCor

    Device will be used in order to record an electrocardiogram during symptoms perceived to be AF. All patients will be instructed to transmit at least once per week.

06

What researchers measure

Primary outcomes

  1. Freedom From Recurrent Atrial Arrhythmias Between 3 to 12 Months After a Single Ablation to Eliminate Atrial Fibrillation (AF)

    Results reflect participants who did not experience a recurrent atrial arrhythmia between 3 to 12 months after receiving an ablation. There was a 3-month blanking period after ablation during which recurrent atrial arrhythmias did not contribute to the primary endpoint's results.

    Time frame: 12 months after ablation

Secondary outcomes

  1. Median Time to Recurrence of Atrial Fibrillation After a 3 Month Blanking Period of Ablation

    Results reflect the median time in days for the recurrence of atrial fibrillation 3 months after ablation.

    Time frame: up to 1 year after ablation

  2. Freedom From Recurrent Atrial Arrhythmias at 6 Months After Ablation After the Blanking Period of 3 Months

    Results reflect participants who did not experience a recurrent atrial arrhythmia between 3 to 6 months after receiving an ablation. There was a 3-month blanking period after ablation during which recurrent atrial arrhythmias did not contribute to the secondary endpoint's results.

    Time frame: 3 to 6 months after ablation

  3. Freedom From Recurrent Atrial Arrhythmias at 6 Months After Repeat Ablation

    Results reflect participants who did not experience a recurrent atrial arrhythmia between 3 to 6 months after receiving a repeat ablation. There was a 3-month blanking period after ablation during which recurrent atrial arrhythmias did not contribute to the secondary endpoint's results.

    Time frame: 6 months after a repeated ablation

  4. Atrial Fibrillation Severity Score (AFSS) - Part C

    There were a total of 7 questions in this questionnaire. This collected information regarding the participants atrial fibrillation for subjects to report severity of symptoms (i.e. palpitations, shortness of breath at rest/physical activity, exercise intolerance, fatigue at rest, and lightheadedness/dizziness, chest pain or pressure) on a Likert scale from 0 (subject did not have this symptom) to 5 (symptom bothers subject a great deal). The total range of the scale was 0 to 35, with 0 meaning no symptoms and 35 meaning maximum number of symptoms.

    Time frame: 12 months after ablation

  5. Change in Weight at 3 Months After Ablation

    Results reflect change in weight from baseline 3 months after ablation.

    Time frame: Baseline and 3 months after ablation

  6. Change in Weight at 6 Months After Ablation

    Results reflect change in weight from baseline 6 months after ablation.

    Time frame: Baseline and 6-months after ablation

  7. Change in Hemoglobin A1c at 6 Months After Ablation

    Results reflect change in A1c from baseline 6 months after ablation.

    Time frame: Baseline and 6-months after ablation

  8. Change in Hemoglobin A1C at 12 Months After Ablation

    Results reflect change in A1c from baseline 12 months after ablation.

    Time frame: Baseline and 12-months after ablation

  9. Number of Participants With Major Procedural Complication up to 30 Days Post-Ablation

    Results reflect number of participants who experienced a major procedural complication following ablation. Complications included but were not limited to major bleeding, vascular injury, myocardial perforation, stroke, and mortality.

    Time frame: up to 30 days

  10. Atrial Fibrillation Related Morbidity During Follow-up

    During follow-up visits information was collected regarding Emergency department visits and hospital admissions due to Atrial Fibrillation, Transient Ischemic Attack (TIA)/cerebrovascular accident (CVA), and mortality. These were collected as total number of participants who experienced one of these events.

    Time frame: up to approximately 1 year after ablation

  11. Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices

    Results reflect the percentage of days during which some form of electrocardiographic monitoring demonstrated atrial fibrillation.

    Time frame: 3 months after ablation

  12. Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices, EKGs, Event Monitoring, Cardiac Implantable Electronic Devices

    Results reflect the percentage of days during which some form of electrocardiographic monitoring demonstrated atrial fibrillation.

    Time frame: 6 months after ablation

  13. Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices

    Results reflect the percentage of days during which some form of electrocardiographic monitoring demonstrated atrial fibrillation.

    Time frame: 1 year after ablation

07

Results

Posted Oct 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneMetforminStandard of Care
Started4950
Completed4950
Not completed00

Outcome measures

PrimaryFreedom From Recurrent Atrial Arrhythmias Between 3 to 12 Months After a Single Ablation to Eliminate Atrial Fibrillation (AF)

Results reflect participants who did not experience a recurrent atrial arrhythmia between 3 to 12 months after receiving an ablation. There was a 3-month blanking period after ablation during which recurrent atrial arrhythmias did not contribute to the primary endpoint's results.

Time frame:
12 months after ablation
Reported as:
Count of participants · Participants
Freedom From Recurrent Atrial Arrhythmias Between 3 to 12 Months After a Single Ablation to Eliminate Atrial Fibrillation (AF)
ParticipantsMetforminStandard of Care
Freedom From Recurrent Atrial Arrhythmias Between 3 to 12 Months After a Single Ablation to Eliminate Atrial Fibrillation (AF)3829
Statistical analysis
  • Metformin vs Standard of Care · Hazard ratio (hr): 0.5 · 95% CI 0.2 to 0.9
SecondaryMedian Time to Recurrence of Atrial Fibrillation After a 3 Month Blanking Period of Ablation

Results reflect the median time in days for the recurrence of atrial fibrillation 3 months after ablation.

Time frame:
up to 1 year after ablation
Reported as:
Median · Days
Median Time to Recurrence of Atrial Fibrillation After a 3 Month Blanking Period of Ablation
DaysMetforminStandard of Care
Median Time to Recurrence of Atrial Fibrillation After a 3 Month Blanking Period of AblationNA (NA to NA)NA (NA to NA)
SecondaryFreedom From Recurrent Atrial Arrhythmias at 6 Months After Ablation After the Blanking Period of 3 Months

Results reflect participants who did not experience a recurrent atrial arrhythmia between 3 to 6 months after receiving an ablation. There was a 3-month blanking period after ablation during which recurrent atrial arrhythmias did not contribute to the secondary endpoint's results.

Time frame:
3 to 6 months after ablation
Reported as:
Count of participants · Participants
Freedom From Recurrent Atrial Arrhythmias at 6 Months After Ablation After the Blanking Period of 3 Months
ParticipantsMetforminStandard of Care
Freedom From Recurrent Atrial Arrhythmias at 6 Months After Ablation After the Blanking Period of 3 Months4240
SecondaryFreedom From Recurrent Atrial Arrhythmias at 6 Months After Repeat Ablation

Results reflect participants who did not experience a recurrent atrial arrhythmia between 3 to 6 months after receiving a repeat ablation. There was a 3-month blanking period after ablation during which recurrent atrial arrhythmias did not contribute to the secondary endpoint's results.

Time frame:
6 months after a repeated ablation
Reported as:
Count of participants · Participants
Freedom From Recurrent Atrial Arrhythmias at 6 Months After Repeat Ablation
ParticipantsMetforminStandard of Care
Freedom From Recurrent Atrial Arrhythmias at 6 Months After Repeat Ablation24
SecondaryAtrial Fibrillation Severity Score (AFSS) - Part C

There were a total of 7 questions in this questionnaire. This collected information regarding the participants atrial fibrillation for subjects to report severity of symptoms (i.e. palpitations, shortness of breath at rest/physical activity, exercise intolerance, fatigue at rest, and lightheadedness/dizziness, chest pain or pressure) on a Likert scale from 0 (subject did not have this symptom) to 5 (symptom bothers subject a great deal). The total range of the scale was 0 to 35, with 0 meaning no symptoms and 35 meaning maximum number of symptoms.

Time frame:
12 months after ablation
Reported as:
Mean · score on a scale
Atrial Fibrillation Severity Score (AFSS) - Part C
score on a scaleMetforminStandard of Care
Atrial Fibrillation Severity Score (AFSS) - Part C2.7 ± 6.15 ± 8
Statistical analysis
  • Metformin vs Standard of Care · Mixed Models Analysis · p = 0.8
SecondaryChange in Weight at 3 Months After Ablation

Results reflect change in weight from baseline 3 months after ablation.

Time frame:
Baseline and 3 months after ablation
Reported as:
Mean · Kilograms
Change in Weight at 3 Months After Ablation
KilogramsMetforminStandard of Care
Change in Weight at 3 Months After Ablation-5.1 ± 4.1-7 ± 3.1
SecondaryChange in Weight at 6 Months After Ablation

Results reflect change in weight from baseline 6 months after ablation.

Time frame:
Baseline and 6-months after ablation
Reported as:
Mean · Kilograms
Change in Weight at 6 Months After Ablation
KilogramsMetforminStandard of Care
Change in Weight at 6 Months After Ablation0.4 ± 4.80.3 ± 3.2
SecondaryChange in Hemoglobin A1c at 6 Months After Ablation

Results reflect change in A1c from baseline 6 months after ablation.

Time frame:
Baseline and 6-months after ablation
Reported as:
Mean · percentage of glycated hemoglobin
Change in Hemoglobin A1c at 6 Months After Ablation
percentage of glycated hemoglobinMetforminStandard of Care
Change in Hemoglobin A1c at 6 Months After Ablation0.09 ± 0.30.06 ± 0.3
SecondaryChange in Hemoglobin A1C at 12 Months After Ablation

Results reflect change in A1c from baseline 12 months after ablation.

Time frame:
Baseline and 12-months after ablation
Reported as:
Mean · percentage of glycated hemoglobin
Change in Hemoglobin A1C at 12 Months After Ablation
percentage of glycated hemoglobinMetforminStandard of Care
Change in Hemoglobin A1C at 12 Months After Ablation5.6 ± 1.25.7 ± 0.4
Statistical analysis
  • Metformin vs Standard of Care · Mixed Models Analysis · p = 0.6
SecondaryNumber of Participants With Major Procedural Complication up to 30 Days Post-Ablation

Results reflect number of participants who experienced a major procedural complication following ablation. Complications included but were not limited to major bleeding, vascular injury, myocardial perforation, stroke, and mortality.

Time frame:
up to 30 days
Reported as:
Count of participants · Participants
Number of Participants With Major Procedural Complication up to 30 Days Post-Ablation
ParticipantsMetforminStandard of Care
Number of Participants With Major Procedural Complication up to 30 Days Post-Ablation00
SecondaryAtrial Fibrillation Related Morbidity During Follow-up

During follow-up visits information was collected regarding Emergency department visits and hospital admissions due to Atrial Fibrillation, Transient Ischemic Attack (TIA)/cerebrovascular accident (CVA), and mortality. These were collected as total number of participants who experienced one of these events.

Time frame:
up to approximately 1 year after ablation
Reported as:
Count of participants · Participants
Atrial Fibrillation Related Morbidity During Follow-up
ParticipantsMetforminStandard of Care
Atrial Fibrillation Related Morbidity During Follow-up53
SecondaryBurden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices

Results reflect the percentage of days during which some form of electrocardiographic monitoring demonstrated atrial fibrillation.

Time frame:
3 months after ablation
Reported as:
Median · Percentage of Days
Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices
Percentage of DaysMetforminStandard of Care
Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices0 (0 to 14)0 (0 to 28)
SecondaryBurden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices, EKGs, Event Monitoring, Cardiac Implantable Electronic Devices

Results reflect the percentage of days during which some form of electrocardiographic monitoring demonstrated atrial fibrillation.

Time frame:
6 months after ablation
Reported as:
Median · Percentage of Days
Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices, EKGs, Event Monitoring, Cardiac Implantable Electronic Devices
Percentage of DaysMetforminStandard of Care
Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices, EKGs, Event Monitoring, Cardiac Implantable Electronic Devices0 (0 to 0)0 (0 to 18)
SecondaryBurden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices

Results reflect the percentage of days during which some form of electrocardiographic monitoring demonstrated atrial fibrillation.

Time frame:
1 year after ablation
Reported as:
Median · Percentage of Days
Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices
Percentage of DaysMetforminStandard of Care
Burden of Atrial Fibrillation Assessed by AliveCOR Kardia Devices0 (0 to 0)0 (0 to 25)
Statistical analysis
  • Metformin vs Standard of Care · Wilcoxon (Mann-Whitney) · p = 0.03

Adverse events

Collected over 13 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Metformin0/49 (0%)5/49 (10.2%)12/49 (24.5%)
Standard of Care0/50 (0%)3/50 (6%)0/50 (0%)
Most frequent serious events
Most frequent serious events
EventMetforminStandard of Care
Atrial fibrillation (hospital admission)Cardiac disorders5/493/50
Most frequent other events
Most frequent other events
EventMetforminStandard of Care
Gastrointestinal intolerance (diarrhea/nausea)Gastrointestinal disorders12/490/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)MetforminStandard of CareTotal
Mean62 ± 8.263.2 ± 10.563 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)MetforminStandard of CareTotal
Female121830
Male373269
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MetforminStandard of CareTotal
Hispanic or Latino011
Not Hispanic or Latino454691
Unknown or Not Reported437
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MetforminStandard of CareTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White414889
More than one race202
Unknown or Not Reported527
Region of Enrollment
Region of Enrollment(Participants)MetforminStandard of CareTotal
United States495099
Type of Atrial Fibrillation (Paroxysmal vs. Persistent)
Type of Atrial Fibrillation (Paroxysmal vs. Persistent)(Participants)MetforminStandard of CareTotal
Paroxysmal (≤7 days)242246
Persistent (≥8 days)252853
History of Prior Ablation
History of Prior Ablation(Participants)MetforminStandard of CareTotal
Count of participants13922
Weight
Weight(kilograms)MetforminStandard of CareTotal
Mean102.8 ± 17.7104.0 ± 21.2103.4 ± 19.5

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jul 2025, 53 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 53 months is close to that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2020
First posted
Nov 12, 2020
StartActual
Jan 19, 2021
Primary completionActual
Jul 1, 2025
CompletionActual
Aug 10, 2025
Results first posted
Oct 6, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedFreedom from recurrent atrial arrhythmias byFrom Recurrent Atrial Arrhythmias Between 3 to 12 months afterMonths After a single ablationSingle Ablation to eliminate Eliminate Atrial Fibrillation (AF)Time frame: 12 months after ablation
Oct 6, 2026
Secondary outcomes
13 edited
What changed in the outcomes
  • EditedMedian Time to recurrenceRecurrence of atrial fibrillation afterAtrial Fibrillation After a 3 month blanking periodMonth Blanking Period of ablationAblationTime frame: up to 1 year after after ablation → up to 1 year after ablation
  • EditedFreedom from recurrent atrial arrhythmiasFrom Recurrent Atrial Arrhythmias at 1 year after ablation after6 Months After Ablation After the blanking periodBlanking Period of 3 monthsMonthsTime frame: 6 months after ablation → 3 to 6 months after ablation
  • EditedFreedom from recurrent atrial arrhythmiasFrom Recurrent Atrial Arrhythmias at 6 months after repeat ablationMonths After Repeat AblationTime frame: 6 months after a repeated ablation
  • EditedAtrial Fibrillation Severity Score (AFSS) - Part CTime frame: up to 12 months after ablation → 12 months after ablation
  • EditedPercent changeChange in weightWeight at 3 months after ablationMonths After AblationTime frame: 3 months after ablation → Baseline and 3 months after ablation
  • EditedPercent changeChange in weightWeight at 6 months after ablationMonths After AblationTime frame: 6 months after ablation → Baseline and 6-months after ablation
  • EditedPercent changeChange in hemoglobinHemoglobin A1c at 6 months after ablationMonths After AblationTime frame: 6 months after ablation → Baseline and 6-months after ablation
  • EditedPercent changeChange in hemoglobinHemoglobin A1C at 12 months after ablationMonths After AblationTime frame: 12 months after ablation → Baseline and 12-months after ablation
  • EditedAtrial Fibrillation related morbidity during followRelated Morbidity During Follow-upTime frame: up to approximately 1 year after ablation
  • EditedBurden of Atrial Fibrillation assessedAssessed by AliveCOR Kardia DevicesTime frame: 6 months after ablation → 3 months after ablation
  • EditedBurden of Atrial Fibrillation assessedAssessed by AliveCOR Kardia Devices, EKGs, Event Monitoring, Cardiac Implantable Electronic DevicesTime frame: 1 year after ablation → 6 months after ablation
  • EditedBurden of Atrial Fibrillation assessedAssessed by AliveCOR Kardia DevicesTime frame: 3 months after ablation → 1 year after ablation
  • ChangedBefore Incidence of major procedural complicationsNow Number of Participants With Major Procedural Complication up to 30 Days Post-AblationTime frame: up to 30 days
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedFreedom from recurrent atrial arrhythmias byFrom Recurrent Atrial Arrhythmias Between 3 to 12 months afterMonths After a single ablationSingle Ablation to eliminate Eliminate Atrial Fibrillation (AF)Time frame: 12 months after ablation
    Secondary outcomes 13 edited
    What changed in the outcomes
    • EditedMedian Time to recurrenceRecurrence of atrial fibrillation afterAtrial Fibrillation After a 3 month blanking periodMonth Blanking Period of ablationAblationTime frame: up to 1 year after after ablation → up to 1 year after ablation
    • EditedFreedom from recurrent atrial arrhythmiasFrom Recurrent Atrial Arrhythmias at 1 year after ablation after6 Months After Ablation After the blanking periodBlanking Period of 3 monthsMonthsTime frame: 6 months after ablation → 3 to 6 months after ablation
    • EditedFreedom from recurrent atrial arrhythmiasFrom Recurrent Atrial Arrhythmias at 6 months after repeat ablationMonths After Repeat AblationTime frame: 6 months after a repeated ablation
    • EditedAtrial Fibrillation Severity Score (AFSS) - Part CTime frame: up to 12 months after ablation → 12 months after ablation
    • EditedPercent changeChange in weightWeight at 3 months after ablationMonths After AblationTime frame: 3 months after ablation → Baseline and 3 months after ablation
    • EditedPercent changeChange in weightWeight at 6 months after ablationMonths After AblationTime frame: 6 months after ablation → Baseline and 6-months after ablation
    • EditedPercent changeChange in hemoglobinHemoglobin A1c at 6 months after ablationMonths After AblationTime frame: 6 months after ablation → Baseline and 6-months after ablation
    • EditedPercent changeChange in hemoglobinHemoglobin A1C at 12 months after ablationMonths After AblationTime frame: 12 months after ablation → Baseline and 12-months after ablation
    • EditedAtrial Fibrillation related morbidity during followRelated Morbidity During Follow-upTime frame: up to approximately 1 year after ablation
    • EditedBurden of Atrial Fibrillation assessedAssessed by AliveCOR Kardia DevicesTime frame: 6 months after ablation → 3 months after ablation
    • EditedBurden of Atrial Fibrillation assessedAssessed by AliveCOR Kardia Devices, EKGs, Event Monitoring, Cardiac Implantable Electronic DevicesTime frame: 1 year after ablation → 6 months after ablation
    • EditedBurden of Atrial Fibrillation assessedAssessed by AliveCOR Kardia DevicesTime frame: 3 months after ablation → 1 year after ablation
    • ChangedBefore Incidence of major procedural complicationsNow Number of Participants With Major Procedural Complication up to 30 Days Post-AblationTime frame: up to 30 days
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04625946
Responsible party
Hakan Oral (Professor of Internal Medicine, University of Michigan) — Principal investigator
First posted
Nov 12, 2020
Start date
Jan 19, 2021
Primary completion
Jul 1, 2025
Completion
Aug 10, 2025
Results posted
Oct 6, 2026
Last update
Oct 6, 2026

Study contacts

Hakan Oral, MD
principal investigator · University of Michigan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion